SC Pharmaceuticals(SZ:002693)2025-05-13 09:18Group 1: Company Performance and Strategies - The company plans to increase R&D investment to enhance product market share and revenue [1][3][6] - Expansion of entrusted business to improve revenue generation capabilities [1][3][6] - Optimization of operational processes to reduce operating costs and enhance profitability [1][3][6] - Streamlining organizational structure to improve operational efficiency and control labor costs [1][3][6] - Expansion of export activities to create new profit growth points [1][3][6] Group 2: Risk Management and Future Plans - The company is actively taking measures to mitigate delisting risks, including adapting to new healthcare policies and participating in procurement [6][9] - Focus on maintaining existing customer orders in the peptide business while expanding customer channels [7][9] - Commitment to advancing the approval of products under review and engaging in international business development activities [7][9] - Emphasis on cost control measures to enhance efficiency and reduce waste [7][9] Group 3: Acquisition and Restructuring - The company currently has no acquisition plans, and all relevant information will be disclosed through designated media [2][4][8] - Suggestions from investors regarding restructuring and acquisitions have been acknowledged, but no concrete plans are in place [2][3][4][8]